Accelerating adherent cell production for diabetes gene therapy using a scalable fixed-bed bioreactor platform

Cell & Gene Therapy Insights 2022; 8(4), 601

DOI: 10.18609/cgti.2022.088

Published: 21 May 2022
Tom Bongiorno

Watch the video or read the poster to learn about:

  • A novel fixed bed bioreactor specifically designed for high yield viral vector production from adherent cell lines
  • How researchers at the Gittes Lab for Diabetes and Pancreatitis Research at the University of Pittsburgh Medical Center/Children’s Hospital of Pittsburgh demonstrated significant productivity gains using the Ascent FBR system for type 1 diabetes research
  • How the Ascent FBR system enabled the Gittes lab to continuously monitor and control the temperature, pH, and DO of their HEK293 cells, resulting in higher viral productivity

Tom Bongiorno, has expertise in stem cell therapy, bioprocessing, media development and cryopreservation and holds PhD in bioengineering from the Georgia Institute of Technology and a BS in mechanical engineering from the University of Notre Dame.